Protalix BioTherapeutics Management
Management criteria checks 4/4
Protalix BioTherapeutics' CEO is Dror Bashan, appointed in Jun 2019, has a tenure of 7.25 years. total yearly compensation is $1.17M, comprised of 34.4% salary and 65.6% bonuses, including company stock and options. directly owns 3.14% of the company’s shares, worth $6.69M. The average tenure of the management team and the board of directors is 5.7 years and 6.7 years respectively.
Key information
Dror Bashan
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 34.44% |
| CEO tenure | 7.3yrs |
| CEO ownership | 3.1% |
| Management average tenure | 5.7yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Narrative Update • Jun 25
PLX: Maintained Fair Value And 2026 Revenue Mix Will Support Upside
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at $11.00, making only slight adjustments to the discount rate and long-term assumptions that leave the overall price target effectively unchanged. What's in the News Protalix BioTherapeutics reaffirmed its total revenue guidance for 2026 in the range of approximately US$78.0 million to US$83.0 million, according to a recent corporate guidance update.Narrative Update • Jun 05
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have kept their $11.00 price target for Protalix BioTherapeutics unchanged, citing a mix of softer revenue growth and profit margin expectations, along with a very large projected future P/E multiple that offsets only modest tweaks to the discount rate in their models. What's in the News Protalix BioTherapeutics reaffirmed its 2026 total revenue guidance, projecting US$78.0 million to US$83.0 million, which includes a US$25.0 million milestone payment already received from Chiesi.Narrative Update • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).Narrative Update • Apr 26
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts now set Protalix BioTherapeutics' price target at $11.00. The unchanged level reflects only minimal tweaks to inputs such as the discount rate, long term revenue growth, profit margin assumptions and future P/E expectations.Narrative Update • Apr 09
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have maintained their $11.00 price target for Protalix BioTherapeutics, citing relatively stable assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the basis for keeping their outlook unchanged. What's in the News The European Commission approves a 2 mg/kg every four weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every two weeks to every four weeks (Key Developments).Narrative Update • Mar 26
PLX: New Dosing Approval And 2026 Outlook Will Support Undervalued Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, highlighting revised assumptions for revenue growth, profit margins, the discount rate and future P/E as key drivers behind their updated model. What's in the News Protalix BioTherapeutics issued 2026 total revenue guidance of approximately $78.0 million to $83.0 million, which includes a $25.0 million milestone payment from Chiesi tied to regulatory progress for Elfabrio (company guidance).Narrative Update • Mar 09
PLX: Extended Fabry Dosing Will Support Undervalued Long Term Outlook
Analysts have reiterated an $11.00 price target for Protalix BioTherapeutics, citing only slight tweaks to model inputs such as the discount rate, long-term revenue growth, profit margins, and future P/E assumptions rather than any major shift in their overall view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the European Medicines Agency's Committee for Medicinal Product for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy (Key Developments).Narrative Update • Feb 23
PLX: Fabry Dosing Extension Will Support Undervalued Long Term Outlook
Analysts are maintaining their $11.00 price target for Protalix BioTherapeutics while slightly refining core modeling inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions to better align with their updated risk and earnings outlook. What's in the News CHMP of the EMA issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa in adult Fabry disease patients who are stable on enzyme replacement therapy, potentially giving eligible patients a longer interval between infusions (Product related announcement).Narrative Update • Feb 08
PLX: Renal ASO Pipeline And Fabry Dosing Expansion Will Drive Upside
Analysts have maintained their price target for Protalix BioTherapeutics at US$11.00, citing a combination of updated assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple as reasons to keep their existing valuation view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy, aiming to extend time between infusions so patients can focus more on daily life (Key Developments).Narrative Update • Jan 24
PLX: Renal ASO Collaboration Will Drive Next Phase Of Upside Potential
Analysts have maintained their US$11.00 price target for Protalix BioTherapeutics, citing only slight adjustments to their discount rate, long term revenue growth, profit margin assumptions and future P/E outlook, rather than any major shift in their thesis. What's in the News Protalix BioTherapeutics and Secarna Pharmaceuticals entered a collaboration and option agreement to discover antisense oligonucleotide therapies targeting rare renal indications, with Secarna using its OligoCreator platform to design and profile candidates and Protalix selecting the biological targets (Key Developments).Narrative Update • Jan 10
PLX: Renal Collaboration Agreement Will Drive Next Phase Of Upside Potential
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at US$11.00. This reflects only minor adjustments to assumptions around discount rate, revenue growth, profit margins and future P/E that do not materially change their overall view.Narrative Update • Dec 16
PLX: European Label Expansion Review Will Drive Next Phase Of Upside Potential
Analysts have nudged their price target on Protalix BioTherapeutics slightly higher to $11.00, reflecting marginal adjustments to discount rate, long term growth, and profitability assumptions, while maintaining a broadly consistent valuation framework. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics requested re examination of the EMA CHMP negative opinion on adding a once every 4 weeks 2 mg/kg Elfabrio dosing regimen to the currently approved every 2 weeks regimen, seeking broader label flexibility in Europe (Key Developments) Safety data from Elfabrio clinical trials highlighted hypersensitivity reactions in 14 percent of treated patients and anaphylaxis in 3 percent, underscoring the need for careful infusion monitoring and potential dose adjustments (Key Developments) Additional clinical observations included infusion associated reactions in 29 percent of Elfabrio patients and a reported case of membranoproliferative glomerulonephritis, prompting recommendations to monitor renal function and infusion related symptoms (Key Developments) Protalix BioTherapeutics was added to the S&P Global BMI Index, potentially increasing its visibility and accessibility to global institutional investors (Key Developments) Valuation Changes Fair value estimate maintained at $11.00 per share, indicating no change to the analyst target price.Narrative Update • Dec 02
PLX: European Regulatory Review Will Unlock Next Phase Of Upside Potential
Analysts have lowered their price target for Protalix BioTherapeutics from $12.50 to $11.00, citing a slight reduction in expected revenue growth and profit margins. What's in the News Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the negative opinion by the European Medicines Agency regarding the new dosing regimen for Elfabrio.Narrative Update • Nov 18
PLX: European Review Process Will Drive Next Phase Of Momentum
Analysts have lowered their price target for Protalix BioTherapeutics from $14.00 to $12.50. They cite more conservative expectations regarding revenue growth and profit margins.
New Narrative • May 19
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
New Narrative • Apr 29
PRX-115 Trials And Elfabrio Launch Will Open Future Markets
Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.Analysis Article • Feb 22
Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon
We feel now is a pretty good time to analyse Protalix BioTherapeutics, Inc.'s ( NYSEMKT:PLX ) business as it appears...Analysis Article • Jan 14
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...Analysis Article • Dec 10
Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Protalix BioTherapeutics, Inc. ( NYSEMKT:PLX ) can tell us which group is most powerful...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$19m |
| Mar 31 2026 | n/a | n/a | US$15m |
| Dec 31 2025 | US$1m | US$402k | -US$7m |
| Sep 30 2025 | n/a | n/a | US$5m |
| Jun 30 2025 | n/a | n/a | US$6m |
| Mar 31 2025 | n/a | n/a | US$4m |
| Dec 31 2024 | US$2m | US$374k | US$3m |
| Sep 30 2024 | n/a | n/a | -US$10m |
| Jun 30 2024 | n/a | n/a | -US$15m |
| Mar 31 2024 | n/a | n/a | US$7m |
| Dec 31 2023 | US$3m | US$357k | US$8m |
| Sep 30 2023 | n/a | n/a | US$11m |
| Jun 30 2023 | n/a | n/a | US$9m |
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$1m | US$360k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | n/a | n/a | -US$18m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$1m | US$374k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | n/a | n/a | -US$21m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$1m | US$352k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$9m |
| Dec 31 2019 | US$566k | US$175k | -US$18m |
Compensation vs Market: Dror's total compensation ($USD1.17M) is about average for companies of similar size in the US market ($USD1.61M).
Compensation vs Earnings: Dror's compensation has been consistent with company performance over the past year.
CEO
Dror Bashan (59 yo)
7.3yrs
Tenure
US$1,166,934
Compensation
Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019. He has experience in the pharmaceutical industry with roles ranging from busi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.3yrs | US$1.17m | 3.14% $ 6.7m | |
| Senior VP | 1.1yrs | US$539.14k | 0.0045% $ 9.6k | |
| SVP & COO | 8.3yrs | US$575.77k | 0.29% $ 613.3k | |
| Vice President of Human Resources | 4.1yrs | no data | no data |
5.7yrs
Average Tenure
59yo
Average Age
Experienced Management: PLX's management team is seasoned and experienced (5.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.3yrs | US$1.17m | 3.14% $ 6.7m | |
| Independent Director | 18.2yrs | US$71.71k | 0.0093% $ 19.8k | |
| Independent Director | 11.8yrs | US$71.71k | 0.39% $ 819.7k | |
| Independent Director | 6.7yrs | US$71.71k | 0.0093% $ 19.8k | |
| Member of Scientific Advisory Board | 10.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.3yrs | US$71.34k | 0.0093% $ 19.8k | |
| Chairman of Scientific Advisory Board | no data | US$55.00k | no data | |
| Independent Chairman | 3yrs | US$99.58k | 0.0093% $ 19.8k | |
| Independent Director | 6.7yrs | US$71.71k | 0.0094% $ 19.9k | |
| Director | 1.3yrs | US$20.08k | 0.0093% $ 19.8k |
6.7yrs
Average Tenure
73yo
Average Age
Experienced Board: PLX's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 07:49 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Protalix BioTherapeutics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Peter Welford | Jefferies LLC |